Dinutuximab and Intensive Therapy for High-Risk Neuroblastoma in Children

This study focuses on children who have been newly diagnosed with high-risk neuroblastoma, a type of cancer that develops from immature nerve cells. The goal is to find out if adding a drug called dinutuximab to the usual intense cancer treatments can help these children survive longer without their cancer coming back. Researchers want to see if this combination can also improve overall survival rates and how well the cancer responds to treatment at the end of the initial treatment phase. Additionally, they are examining whether this new approach causes different side effects compared to standard treatments and how factors like tumor characteristics and patient conditions affect outcomes. Participants in the study will undergo a series of treatments that include several cycles of chemotherapy drugs administered through an IV, and in some cases, orally. The study involves cycles of treatment, and based on how the tumor responds, patients may proceed to additional cycles or move on to a phase called Consolidation, which includes stem cell transplants. Throughout the study, tests such as scans and biopsies are conducted to evaluate the tumor's response to treatment. The study aims to measure results like event-free survival (how long patients live without the cancer coming back) and overall survival. Potential risks include common side effects of chemotherapy and immunotherapy, but the study also explores possible improvements in survival and quality of life for patients.